Affiliation:
1. National Reference Center for Tuberculosis and Mycobacteria, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium
2. Bruker Daltonik GmbH, Bremen, Germany
3. Health and Environment, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium
4. Mycology & Aerobiology, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium
Abstract
ABSTRACT
Species identification and drug susceptibility testing (DST) of mycobacteria are important yet complex processes traditionally reserved for reference laboratories. Recent technical improvements in matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) has started to facilitate routine mycobacterial identifications in clinical laboratories. In this paper, we investigate the possibility of performing phenotypic MALDI-based DST in mycobacteriology using the recently described MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA). We randomly selected 72 clinical
Mycobacterium tuberculosis
and nontuberculous mycobacterial (NTM) strains, subjected them to MBT-ASTRA methodology, and compared its results to current gold-standard methods. Drug susceptibility was tested for rifampin, isoniazid, linezolid, and ethambutol (
M. tuberculosis
,
n
= 39), and clarithromycin and rifabutin (NTM,
n
= 33). Combined species identification was performed using the Biotyper Mycobacteria Library 4.0.
Mycobacterium
-specific MBT-ASTRA parameters were derived (calculation window,
m/z
5,000 to 13,000, area under the curve [AUC] of >0.015, relative growth [RG] of <0.5; see the text for details). Using these settings, MBT-ASTRA analyses returned 175/177
M. tuberculosis
and 65/66 NTM drug resistance profiles which corresponded to standard testing results. Turnaround times were not significantly different in
M. tuberculosis
testing, but the MBT-ASTRA method delivered on average a week faster than routine DST in NTM. Databases searches returned 90.4% correct species-level identifications, which increased to 98.6% when score thresholds were lowered to 1.65. In conclusion, the MBT-ASTRA technology holds promise to facilitate and fasten mycobacterial DST and to combine it directly with high-confidence species-level identifications. Given the ease of interpretation, its application in NTM typing might be the first in finding its way to current diagnostic workflows. However, further validations and automation are required before routine implementation can be envisioned.
Publisher
American Society for Microbiology
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献